62 results about "Intestinal permeability" patented technology

A nutritional supplement for the prevention and treatment of excessive intestinal permeability is provided. The treatment includes a dietary regimen of nutritional buffers, amino acid chelates, minerals and vitamins. Other components may include antioxidants, free radical scavengers, beneficial organisms, and intestinal tract-soothing herbs.

Methods of treating adverse intestinal effects of a non-steroidal anti-inflammatory drugs (NSAID) in a subject by administering to the subject a therapeutically effective amount of a selective bacterial beta-glucuronidase inhibitor. The adverse intestinal effects to be treated include the formation or growth of an intestinal ulcer, increased intestinal permeability, the loss of intestinal villi, bleeding of the intestinal mucosa, and an increased intestinal inflammatory response. The methods are useful for treating the adverse effects of any NSAID such as propionic acid derivatives, carboxylic acid derivatives, enolic acid derivatives, fenamic acid derivatives, sulphonanilidies, and selective COX-2 inhibitors. The bacterial beta-glucuronidase inhibitors are selective for the inhibition of bacterial beta-glucuronidase enzymes and do not inhibit mammalian beta-glucuronidase.

The invention relates to a synthetic composition comprising one or more human milk monosaccharides and / or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and / or low-grade inflammation in patients with metabolic disorders.

The invention discloses a drug for treating severe acute pancreatitis. The drug is made from bupleurum, corydalis tuber, oriental wormwood, fermented soybean, immature orange fruit, white atractylodes rhizome, oriental water plantain and Chinese aloe according to a certain weight proportion. The drug has protective effect on the intestinal barrier function under the condition of the severe acute pancreatitis, can lower intestinal tract permeability, lighten endotoxemia and inflammatory reaction, and has greater influence on outcome of diseases.

The invention relates to application of bifidobacterium lactis in prevention and treatment of mental disorder, the bifidobacterium lactis is bifidobacterium lactis BL-11, and the preservation number of the bifidobacterium lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The bifidobacterium lactis provided by the invention can be used for improving the intestinal permeability and reducing the levels of LPS and D-lactic acid in blood, so that the effect of preventing and treating mental disorders is achieved, and the mental disorders comprise anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette disease and Escherberg syndrome.

Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome.

Compositions for and methods of preventing or reducing the severity intestinal hyperpermeabilization in an individual are disclosed. Compositions for and methods of preventing or reducing the severity of a disease or condition caused or exacerbated by intestinal hyperpermeabilization in an individual identified as being at risk of a disease or condition caused or exacerbated by intestinal hyperpermeabilization are also disclosed. Compositions for and methods of treating an individual who has been identified as having a disease or condition caused or exacerbated by intestinal hyperpermeabilization are additionally disclosed.

Permeability models and methods for creating the models are disclosed. The models include receiving as an input in vitro permeability and structure data for a particular compound. Then the data is mapped to at least one permeability. In some models the data is mapped to a plurality of permeabilities, each associated with a specific region in a mammalian GI tract. Some models may take into consideration solubility, permeability and at least one molecular descriptor associated with the compound of interest.

The invention discloses application of spermidine in preparing medicine for treating the impaired intestinal barrier function. An in vivo and in vitro cell and intestinal permeability increase model is built through lipopolysaccharide stimulation, and the regulation and mechanism of the spermidine on the intestinal barrier function are studied through mutual corroboration.

The invention discloses a probiotic strain for improving intestinal barrier function and application thereof, and relates to the field of probiotics. The probiotic strains provided by the invention are lactobacillus plantarum, pediococcus acidilactici, enterococcus faecium and escherichia coli; wherein the microbial preservation number of the lactobacillus plantarum is CGMCC No.17941; the microbial preservation number of the pediococcus acidilactici is CGMCC No.17943; the microbial preservation number of the enterococcus faecium is CGMCC No.17944; and the microbial preservation number of the escherichia coli is CGMCC No.17945. The probiotic strain provided by the invention can significantly inhibit the increase of intestinal permeability caused by intestinal barrier function damage and recover the intestinal permeability to a healthy level; can effectively relieve colitis and systemic inflammation symptoms caused by intestinal barrier function damage; in addition, the probiotic strain also has the effects of delaying senescence and prolonging the service life. The probiotic strain can be widely applied to products such as drugs for improving intestinal barrier function damage and related development diseases and delaying senescence, and the market application value is high.

The invention relates to a synthetic composition comprising one or more human milk monosaccharides and / or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and / or low-grade inflammation in patients with metabolic disorders.

Supramolecular particle compositions based on medicinal natural products (MNPs), their synthetic analogs and derivatives, and methods to prepare and use them are provided. Five classes of MNPs and their derivatives including diterpene resin acid, phytosterol, lupane-type pentacyclic triterpene, oleanane-type pentacyclic tritepene, and lanostane-type triterpene form functional nano- or micro-structures that are stable to strong acidic environment and effectively penetrate the gastrointestinal tract. Therapeutic, prophylactic, or diagnostic agents that generally have poor intestinal permeability are converted to bioavailable forms when delivered with these supramolecular particles. Among many others, small compound chemotherapeutic agents and peptide therapeutics encapsulated therein have a much greater plasma concentration following oral administration, and effectively controls and treat symptoms associated with tumors or diabetes.

The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR2). Also provided is a single step method for determining severity of an immune-mediated disease in a subject by identifying a genotype for haptoglobin 2 in a biological sample from the subject. A homozygous genotype correlates to 2 copies of zonulin and a more severe disease than a heterozygous genotype correlating to 1 copy of zonulin.

The present invention relates to a nutritional composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising at least one N- acetylated oligosaccharide, one galacto-oligosaccharide and one sialylated oligosaccharide for use in reducing the metabolic stress in an infant in the first twelve months of life and / or decreasing gut permeability in an infant in the first twelve months of life and / or promoting a rate of growth in an infant fed with said nutritional composition in the first twelve months of life which approximates to the rate of growth of a breast-fed infant at the same age.

The invention discloses a strain of bacteroides vulgatus capable of protecting intestinal permeability and application thereof, and belongs to the technical field of microorganisms. The bacteroides vulgatus CCFM1152 provided by the invention has been preserved in the Guangdong Microbial Culture Collection Centre on November 9, 2020, and the preservation number is GDMCC No.61279. The bacteroides vulgatus CCFM1152 provided by the invention can effectively prevent weight loss and shortened colon length induced by DSS, reduce intestinal permeability and repair colonic mucosa injury. Therefore, the bacteroides vulgatus CCFM1152 has a wide application prospect in the aspect of preparing food and microecological preparations for protecting the intestinal permeability.

The invention discloses a probiotics composition and application thereof and a probiotics product. The probiotics composition comprises in parts by weight: 20 to 40 parts of parabacteroides distasonis, 20 to 40 parts of christensenella minuta and 20 to 40 parts of akkermansia muciniphila. By the probiotics composition containing the parabacteroides distasonis, the christensenella minuta and the akkermansia muciniphila in a specific proportion, intestinal permeability can be effectively reduced and the intestinal inflammation level is reduced, so that an intestinal physical barrier, chemical barrier and immunologic barrier can be effectively improved, and intestinal barrier function abnormalities caused by diet / metabolic diseases is obviously improved or relieved; and the probiotics composition can be widely used for preparing drugs, foods or health care products for regulating intestinal barrier functions. Moreover, the probiotics composition also can improve a case of body weight, blood glucose level or blood lipid level abnormalities caused by the metabolic disease.

The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

The invention relates to the fields of chemical pharmacy, medicinal preparations, pharmacokinetics and pharmacodynamics, specifically to a berberine-sodium caprate multi-component solid dispersion and a preparation method and pharmacological activity thereof. The berberine-sodium caprate multi-component solid dispersion is characterized in that berberine, the absorption promoting agent sodium caprate and a solid dispersion carrier are employed to prepare the berberine-sodium caprate solid dispersion, wherein berberine is dispersed in the solid dispersion in an amorphous form. The berberine-sodium caprate solid dispersion provided by the invention has the following advantages: the preparation method is simple and is easy to operate, and solubility and intestinal permeability of berberine are substantially improved, thereby improving bioavailability. The berberine-sodium caprate solid dispersion has substantial treatment effects on diabetes, diabetic complications like diabetic cardiomyopathy, diabetic great vascular complications, diabetic encephalopathy and diabetic eye diseases (retinopathy) and diseases related to diabetes. The berberine-sodium caprate solid dispersion has widely available raw materials, is convenient to use and provides a novel candidate drug for treating diabetes and complications thereof.

The present invention provides rebamipide for use in a method of preventing and / or treating Crohn's disease. In particular, rebamipide is used to prevent and / or treat Crohn's disease in a person suffering from or at risk of increased intestinal permeability.

The invention discloses an application of a pueraria flower extract in preparation of drugs for preventing, treating and relieving inflammatory bowel diseases, protecting intestinal barriers and stabilizing intestinal morphology, provides a reliable anti-inflammatory agent to help to maintain the balance of the intestinal environment, and has the advantages of good curative effect on the inflammatory bowel diseases, low price and no obvious side effect. The invention finds and verifies that the pueraria flower extract has a remarkable curative effect on inflammatory bowel diseases, is low in price and side effect, and can macroscopically improve the intestinal inflammation state by improving the body health level, reducing the intestinal permeability, prolonging the intestinal length and the like. The pueraria flower extract can relieve excessive proliferation and differentiation of precursor cells caused by exogenous proinflammatory factors by negatively regulating an important factor, namely a JAK-STAT signal channel, of a colitis pathogenesis and maintain the homeostasis of intestinal cells, so that the effect of treating the inflammatory bowel disease is achieved.

The present application discloses a strain of lactobacillus plantarum for relieving mental stress and an application thereof. Unhealthy emotions and mental states such as stress, anxiety and depression can increase intestinal permeability and reduce immunity of a body. Both of the factors cause change on microbial populations, and result in microbial displacement due to weakened intestinal immuneprotection. Clinical studies show that the lactobacillus plantarum P-8 relieves stress and anxiety in stressed people by regulating metabolic pathways and anti-inflammatory properties.

The present disclosure relates to a method for quantifying sugar appearing in a biological fluid of a subject, the method comprising: (a) obtaining a biological sample from a subject, who has ingested one or more sugars, over a period of 0 to 24 hours after the ingesting; and (b) measuring the amount of the one or more sugars in the biological sample with an organoborane compound coupled to a fluorophore. Disclosed are also assays and kits for performing the above methods.

The invention provides 5-nornobiletin as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides an application of 5-nornobiletin in preparation of a product for preventing and treating ulcerative colitis, and provides a remarkable prevention and treatment effect of 5-nornobiletin on ulcerative colitis for the first time. The conditions of diarrhea degree, shortened colon length, intestinal congestion, edema and ulcer, intestinal epithelium injury, intestinal permeability increase and the like can be obviously improved. And high-throughput screening and PT-qPCR show that the 5-nornobiletin enhances the barrier effect of intestinal mucosa by up-regulating the expression of intestinal mucosa epithelium mucoprotein Muc2, thereby achieving the purpose of preventing and treating ulcerative colitis. In addition, the demethylation of the polymethoxy flavone nobiletin is accelerated by adopting an acid catalysis and heating method, the conversion from the polymethoxy flavone nobiletin to the 5-nornobiletin is successfully realized, and the purity of the obtained 5-nornobiletin can reach 97.5%.

The invention provides a traditional Chinese medicine compound clysis preparation. The traditional Chinese medicine compound clysis preparation is prepared from the following raw material medicines in parts by mass: 10-15 parts of radix bupleuri, 10-15 parts of radix scutellariae, 12-15 parts of herba artemisiae scopariae, 13-15 parts of fructus gardenia, 10-15 parts of cortex magnoliae officinalis, 10-15 parts of fructus aurantii immaturus, 10-18 parts of rhizoma corydalis, 12-16 parts of radix paeoniae alba, 20-35 parts of dandelion, 22-36 parts of folium isatidis, 20-40 parts of Houttuynia cordata, 12-20 parts of rheum officinale and 25-35 parts of natrii sulfas. Compared with external traditional Chinese medicines, the traditional Chinese medicine compound clysis preparation has relatively strong adaptability by virtue of compatibility of traditional Chinese medicines; the preparation can be repeatedly used; the preparation has the characteristics of being capable of diminishing inflammation, promoting gastrointestinal motility, improving intestinal permeability and balancing intestinal floras; the traditional Chinese medicine compound preparation can be absorbed in intestinal mucosas, so that the treatment effect is improved; and a clysis manner is more safe and efficient than an oral taking manner.

The invention relates to an intestinal flora reconstruction method. By the aid of antibiotic pretreatment and probiotic intervention, intestinal flora reconstruction is promoted, intestinal permeability is reduced to enhance intestinal mucosal barriers, and bile acid components are changed to play a certain role in improvement of glucose metabolism.

The invention relates to application of chitosan oligosaccharide in improving intestinal permeability and serving as an oral absorption enhancer of BCSIII drugs, and belongs to the technical field of chitosan oligosaccharide application. The application of the chitosan oligosaccharide in improving the intestinal permeability is based on the principle that the chitosan oligosaccharide can open tight connection between intestinal microvilli epithelial cells to improve the intestinal permeability, and the application of promoting in-vivo absorption of low-permeability drugs is developed. In addition, the invention further discloses the application of the chitosan oligosaccharide serving as the oral absorption enhancer of the BCSIII drugs. The main component in the BCSIII drugs is triflumurin, the chitosan oligosaccharide is taken first to open the tight connection between the intestinal microvilli epithelial cells, then the BCSIII drugs are taken, after the chitosan oligosaccharide and the intestinal mucosa act for a certain time, the opening degree of the tight connection between the epithelial cells is the maximum, and the water-soluble small molecule drugs enter blood circulation from the epithelial cells through trans-cell bypass transport. The chitosan oligosaccharide can be used for promoting oral absorption of the BCSIII drugs difficult to absorb, and the bioavailability of the BCSIII drugs is remarkably or extremely remarkably improved.

The present invention relates to a nutritional composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising at least one N-acetylated oligosaccharide, one galacto-oligosaccharide and one sialylated oligosaccharide for use in reducing the metabolic stress in an infant in the first twelve months of life and / or decreasing gut permeability in an infant in the first twelve months of life and / or promoting a rate of growth in an infant fed with said nutritional composition in the first twelve months of life which approximates to the rate of growth of a breast-fed infant at the same age.

The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

The invention discloses a method for reducing skatole in a live pig. By injecting glutamine dipeptide into the vein of the pig, the intestinal permeability of the pig is reduced, the absorption of thepig intestine to skatole is reduced, and skatole is prevented from entering blood and fat through the intestinal wall of the pig. At the same time, by adding isomaltooligosaccharides, lactic acid bacteria and other additives in daily ration, the content and survival rate of lactic acid bacteria in the intestinal tract of the pig are increased, the intestinal digestion ability of the pig is enhanced, the organic acid secretion of the lactic acid bacteria is promoted, the pH value of the pig intestine is reduced, the skatole conversion rate of tryptophan is then reduced, and the skatole generation in the pig intestine is reduced. The skatole content in the live pig is significantly reduced, the quality of pork is improved, the taste of pork is improved, and bad odor is removed.